IDiyas

For the Inventor, By the Inventor

Horsham, United Kingdom

Andrew James Culshaw

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 6.3

ph-index = 3

Forward Citations = 23(Granted Patents)


Location History:

  • London, GB (2005 - 2011)
  • Horsham, GB (2010 - 2015)
  • Greenford, GB (2014 - 2018)
  • Middlesex, GB (2018)
  • Norfolk, GB (2023)

Company Filing History:

goldMedal16 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2005-2024

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12157737 - Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof (2024-12-03),
2. 11708366 - Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof (2023-07-25),
3. 10112926 - Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-10-30),
4. 10004732 - Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-06-26),
5. 9862711 - Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-01-09),
6. 9102653 - Substituted quinazolinones as vanilloid antagonists (2015-08-11),
7. 8835444 - Cyclohexyl amide derivatives as CRF receptor antagonists (2014-09-16),
8. 8809528 - Quinazolinone derivatives useful as vanilloid antagonists (2014-08-19),
9. 8614213 - Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists (2013-12-24),
10. 8273900 - Organic compounds (2012-09-25),
11. 8211902 - Quinazolinone derivatives useful as vanilloid antagonists (2012-07-03),
12. 7994203 - Organic compounds (2011-08-09),
13. 7915264 - Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain (2011-03-29),
14. 7732435 - Chromone derivatives useful as antagonists of VR1 receptors (2010-06-08),
15. 7045533 - Naphthalene derivatives (2006-05-16),

Title: Innovator Spotlight: Andrew James Culshaw

Introduction: Andrew James Culshaw, an accomplished inventor based in Horsham, GB, has made significant contributions to the field of pharmaceuticals, holding a total of 16 patents. His work focuses on novel compounds with therapeutic applications, establishing him as a prominent figure in innovative drug development.

Latest Patents: Among his latest patents is a groundbreaking discovery titled "Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof." This invention encompasses a specific compound, including various pharmaceutically acceptable salts, defined by a formula (I). Culshaw's invention not only details a method for manufacturing these compounds but also elucidates their potential therapeutic benefits. Additionally, he has provided a combination of pharmacologically active agents and a pharmaceutical composition, underscoring the importance of his work in advancing medical treatment options.

Career Highlights: Andrew James Culshaw's career is marked by his commitment to innovation within the pharmaceutical industry. Currently employed at Novartis AG, he has become an integral part of a team focused on creating cutting-edge solutions for health-related challenges. His ability to translate complex scientific concepts into practical applications has earned him recognition within his field and a reputation as a leading inventor.

Collaborations: Throughout his career, Culshaw has collaborated with esteemed colleagues, including Christopher Thomas Brain and Edward Karol Dziadulewicz. These partnerships have facilitated a dynamic exchange of ideas and advancements, allowing for the acceleration of innovative projects and contributing to the success of their shared endeavors.

Conclusion: Andrew James Culshaw stands out as a leading innovator in the pharmaceutical sector, with a significant portfolio of patents that reflect his dedication to improving healthcare. His recent contributions illustrate the impactful nature of his work, positioning him as a key player in the ongoing advancement of medicinal therapies. As he continues to innovate alongside talented colleagues, the future of pharmaceutical research appears promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…